Search results
Revascularisation in Patients with Cancer
Added:
3 months ago
Review Article
Added:
1 month ago
American College of Cardiology Congress 2026 - Dr Joost Daemen (Thoraxcenter, Erasmus University Medical Center, Rotterdam, NL) joins us to discuss findings from the FAST III trial (NCT04931771; ECRI) a large-scale randomised study comparing fractional flow reserve (FFR) with 3D-quantitative coronary angiography-derived vessel FFR (vFFR) to guide coronary revascularisation.This randomised, open…
View more
Added:
5 months ago
Added:
6 months ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses…
View more
Targeting Obesity for Heart Failure
Added:
4 months ago
Review Article
Added:
1 year ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory…
View more
Added:
4 weeks ago
Source:
Radcliffe CVRM
Recent US guidelines have controversially recommended lowering the low-density lipoprotein cholesterol (LDL-C) target to <55 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD).¹˒² The Ez-PAVE trial is the first randomised study to directly compare this intensive target with a conventional target of <70 mg/dL. The findings were published in The New England…
View more
Added:
1 month ago
Source:
Cardiac Failure Review
The optimal timing for complete revascularisation in patients with ST-segment elevation myocardial infarction (STEMI) and multi-vessel disease who also present with heart failure is a key clinical question. A pre-specified subgroup analysis of the OPTION-STEMI trial suggests that a staged approach may be preferable to immediate complete revascularisation in this high-risk patient group…
View more
Added:
11 months ago
EuroPCR 25 - 10-year outcomes from DANAMI-3-PRIMULTI show FFR-guided complete revascularisation in ST-elevation myocardial infarction (STEMI) reduces the risk of future events. We are joined by Dr Thomas Engstrøm (University of Copenhagen, Copenhagen, Denmark) to discuss 10-year outcomes from the multicenter, randomized DANAMI-3-PRIMULTI trial investigating FFR-guided complete…
View more
Added:
2 months ago
Source:
ICR3 Journal Radcliffe Cardiology
The optimal timing for treating nonculprit lesions in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease remains a topic of clinical debate. The iMODERN trial sought to clarify this by comparing outcomes between an immediate, physiology-guided percutaneous coronary intervention (PCI) strategy and a deferred, imaging-guided approach.¹˒²MethodologyThe…
View more